These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27889014)

  • 1. [The role of alpha blockers in the treatment of lower urinary tract symptoms/benign prostatic hyperplasia: are all the same? Silodosin in "real life"].
    Alcántara Montero A;
    Semergen; 2016 Jul; 42 Suppl 2():1-9. PubMed ID: 27889014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Osman NI; Chapple CR; Cruz F; Desgrandchamps F; Llorente C; Montorsi F
    Expert Opin Pharmacother; 2012 Oct; 13(14):2085-96. PubMed ID: 22924980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
    Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
    Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
    Ichihara K; Masumori N; Iwasawa A; Taguchi K; Yamaguchi Y; Nishimura M; Sasamura H; Suzuki N; Haga K; Miyao N; Hirose T
    Int J Urol; 2018 Oct; 25(10):849-854. PubMed ID: 30066966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Jung JH; Kim J; MacDonald R; Reddy B; Kim MH; Dahm P
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012615. PubMed ID: 29161773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
    Fonseca J; Martins da Silva C
    Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.
    Keating GM
    Drugs; 2015 Feb; 75(2):207-17. PubMed ID: 25575983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silodosin in the treatment of benign prostatic hyperplasia.
    Rossi M; Roumeguère T
    Drug Des Devel Ther; 2010 Oct; 4():291-7. PubMed ID: 21116335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
    Osman NI; Chapple CR; Tammela TL; Eisenhardt A; Oelke M
    World J Urol; 2015 May; 33(5):697-706. PubMed ID: 25712312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution of lower urinary tract symptoms under silodosin: factors influencing patients' satisfaction].
    Descazeaud A; Davin JL; De La Taille A; Karsenty G; Kouri G; Zerbib M; Morris V; Allaert FA; Coloby P
    Prog Urol; 2014 Mar; 24(3):196-202. PubMed ID: 24560210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficiency and safety of silodosin for treatment of lower urinary tract symptoms, associated of benign prostatic hyperplasia].
    Krivoborodov GG; Tur EI
    Urologiia; 2019 Jun; (2):67-72. PubMed ID: 31162905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.
    Wu YJ; Dong Q; Liu LR; Wei Q
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):79-84. PubMed ID: 22986578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Matsumoto S; Kasamo S; Hashizume K
    Low Urin Tract Symptoms; 2020 Jan; 12(1):86-91. PubMed ID: 31464384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study.
    Masciovecchio S; Di Pasquale AB; Ranieri G; Romano G; Di Clemente L
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4941-4945. PubMed ID: 29164564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).
    Montorsi F; Gandaglia G; Chapple C; Cruz F; Desgrandchamps F; Llorente C
    Int J Urol; 2016 Jul; 23(7):572-9. PubMed ID: 26969887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Blockers for benign prostatic hyperplasia: the new era.
    Lepor H; Kazzazi A; Djavan B
    Curr Opin Urol; 2012 Jan; 22(1):7-15. PubMed ID: 22080875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A place of silodosin in the treatment of LUTS/BPH according to evidence-based medicine and real clinical practice].
    Kotov SV; Bogdanov DA
    Urologiia; 2021 Nov; (5):94-98. PubMed ID: 34743440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.